ARNI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ARNI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Arno Therapeutics's Total Liabilities for the quarter that ended in Sep. 2016 was $8.07 Mil. Arno Therapeutics's Total Assets for the quarter that ended in Sep. 2016 was $2.36 Mil. Therefore, Arno Therapeutics's Liabilities-to-Assets Ratio for the quarter that ended in Sep. 2016 was 3.43.
The historical data trend for Arno Therapeutics's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arno Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec06 | Dec07 | Dec08 | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | |||||||||||
Liabilities-to-Assets | Get a 7-Day Free Trial | 0.81 | 1.95 | 1.48 | 1.07 | 24.89 |
Arno Therapeutics Quarterly Data | ||||||||||||||||||||
Dec11 | Mar12 | Jun12 | Sep12 | Dec12 | Mar13 | Jun13 | Sep13 | Dec13 | Mar14 | Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | |
Liabilities-to-Assets | Get a 7-Day Free Trial | 13.79 | 24.89 | 2.38 | 5.75 | 3.43 |
For the Biotechnology subindustry, Arno Therapeutics's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Arno Therapeutics's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where Arno Therapeutics's Liabilities-to-Assets falls into.
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
Arno Therapeutics's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2015 is calculated as:
Liabilities-to-Assets (A: Dec. 2015 ) | = | Total Liabilities | / | Total Assets |
= | 8.985 | / | 0.361 | |
= | 24.89 |
Arno Therapeutics's Liabilities-to-Assets Ratio for the quarter that ended in Sep. 2016 is calculated as
Liabilities-to-Assets (Q: Sep. 2016 ) | = | Total Liabilities | / | Total Assets |
= | 8.07 | / | 2.356 | |
= | 3.43 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arno Therapeutics (OTCPK:ARNI) Liabilities-to-Assets Explanation
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
Thank you for viewing the detailed overview of Arno Therapeutics's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
S Donald Sussman | other: See Footnote 1 | 888 EAST LAS OLAS BLVD, SUITE 710, FORT LAUDERDALE FL 33301 |
David M Tanen | director, officer: Secretary | TWO RIVER GROUP HOLDINGS, LLC., 689 FIFTH AVENUE, NEW YORK NY 10022 |
Tomer Kariv | director | C/O ARNO THERAPEUTICS, INC., 200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822 |
Arie Belldegrun | director | UCLA SCHOOL OF MEDICINE, 10833 LE CONTE 66-118 CHS BOX 951738, LOS ANGELES CA 9095-1738 |
Alexander A Zukiwski | director, officer: Chief Executive Officer & CMO | 200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822 |
Jay Moorin | director | C/O PROQUEST INVESTMENTS, L.P, 2430 VANDERBILT BEACH ROAD, #108 - 190, NAPLES FL 34109 |
Lawrence A Kenyon | officer: Chief Financial Officer | C/O OUTLOOK THERAPEUTICS, INC., 7 CLARKE DRIVE, CRANBURY NJ 08512 |
Glenn R. Mattes | director, officer: President & CEO | 200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822 |
Randy H Thurman | director | 222 MERCHANDISE MART PLAZA, SUITE 2024, CHICAGO IL 60654 |
Wexford Gp Llc | other: No longer own 10% of Issuer | C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602 EAST, WEST PALM BEACH CT 33401 |
Joseph Jacobs | other: No longer own 10% of Issuer | C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602 EAST, WEST PALM BEACH FL 33401 |
Wexford Capital Lp | other: No longer own 10% of Issuer | 777 WEST PUTNAM AVENUE, 1ST FLOOR, GREENWICH CT 06830 |
Charles E Davidson | other: No longer own 10% of Issuer | C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602, WEST PALM BEACH FL 33401 |
Ran Nussbaum | 10 percent owner | C/O KITE PHARMA, INC., 2225 COLORADO AVENUE, SANTA MONICA CA 90404 |
Brian Lenz | officer: Chief Financial Officer | 65 COMMERCE WAY, HACKENSACK NJ 07601 |
No Headlines
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.